Irene Becklund, the Principal Accounting Officer (PAO) of Hims & Hers Health, Inc. (NYSE:HIMS), has recently engaged in multiple transactions involving the company’s stock, according to a new SEC filing. Becklund executed sales totaling over $200,000, while also participating in acquisitions of shares through option exercises.
On March 15, 2024, Becklund sold 6,397 shares of Class A Common Stock at a price of $14.63 per share, resulting in a total transaction value of $93,588. Subsequently, on March 18, Becklund exercised options to acquire 472 shares at $9.41 each, amounting to $4,441 in total. On the same day, these shares were sold at a price of $14.70 each, totaling $6,938.
The most significant transaction occurred on March 19, when Becklund sold 13,353 shares at a price of $15.52 per share. This sale amounted to a total of $207,238, making it the largest in the series of recent transactions.
The transactions were conducted under a Rule 10b5-1 trading plan, which allows company insiders to set up a predetermined plan to buy or sell company stocks at a time when they are not in possession of material non-public information. This plan was adopted by Becklund on September 11, 2023.
In addition to these non-derivative transactions, Becklund also engaged in transactions involving restricted stock units (RSUs), which represent a contingent right to receive shares of Class A Common Stock. These RSUs are subject to a service-based vesting requirement and are set to vest over a four-year period with quarterly installments.
Investors tracking insider activity may consider these transactions as part of their analysis of Hims & Hers Health’s stock performance. The company, which is incorporated in Delaware and has its business address in San Francisco, California, operates in the healthcare sector, specifically in services related to offices and clinics of doctors of medicine.
InvestingPro Insights
Amidst the recent insider transactions by Hims & Hers Health, Inc.'s Principal Accounting Officer, Irene Becklund, investors are keenly observing the performance metrics and future outlook of the company. Here are some key insights from InvestingPro that could provide a more comprehensive picture:
The company's market capitalization currently stands at approximately $3.34 billion, reflecting its substantial presence in the healthcare sector. Despite a negative P/E ratio of -138.39, which indicates that the company is not currently profitable, the robust revenue growth of 65.49% over the last twelve months as of Q1 2023 suggests significant market expansion and potential for future profitability.
InvestingPro Tips highlight that while Hims & Hers Health has not been profitable over the last twelve months, analysts predict the company will be profitable this year. This potential turnaround in net income could be a pivotal moment for investors considering the stock's future trajectory. Moreover, the company's strong return over the last year, with a 60.57% price total return, signals that the market has responded positively to its growth initiatives.
Another notable InvestingPro Tip is the company's liquid assets exceeding short-term obligations, indicating a healthy liquidity position that could support ongoing operations and strategic investments. Additionally, Hims & Hers Health is trading near its 52-week high, with the price at 99.4% of this benchmark, which could suggest investor confidence or, as per another tip, signal that the stock is in overbought territory.
For those interested in gaining more insights and tips, there are additional InvestingPro Tips available for Hims & Hers Health at https://www.investing.com/pro/HIMS. Use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking a wealth of data and analytics to inform your investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.